Clincal Trial Endpoints in Ovarian Cancer

Video

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

The oncology community would like to see a gold standard of improved overall survival or at least a good way to measure clinical benefit, Aghajanian says. Patients with ovarian cancer live for a long time, receive multiple lines of therapy, and often cross over, in a sense, to receive therapies in the same class.

These factors make it difficult to measure overall survival.

Clinical Pearls

  • The oncology community is still developing a good way to measure clinical benefit in ovarian cancer
  • Creating a gold standard endpoint for ovarian cancer is difficult due to patient parameters
Recent Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Related Content